06. 10. 2014
FDA designates Ariad Pharmaceuticals' lung cancer drug AP26113 as breakthrough therapy
Ariad Pharmaceuticals announced Thursday that the FDA granted breakthrough therapy status for its experimental tyrosine kinase inhibitor (TKI) AP26113 to treat patients with anaplastic lymphoma kinase positive (ALK+), metastatic non-small-cell lung cancer (NSCLC) who are resistant to Pfizer's Xalkori (crizotinib).